Moderna’s ($MRNA) reported $181.36 support level is now the key technical reference after mixed melanoma vaccine data triggered a selloff. The Phase 3 trial reduced the risk of melanoma recurrence or death by 42%—a meaningful result, but weaker than the 49% reduction reported in the earlier Phase 2b study.

That gap is the market’s problem to price. Moderna shares had already risen more than 500%, according to the report, leaving investors highly sensitive to any sign that late-stage data may not fully match the earlier readout. With the stock reported to be holding $181.36, the level has become a clear line between data-driven digestion and deeper technical pressure.

Why the data comparison matters

The headline number from the Phase 3 trial remains substantial: a 42% reduction in the risk of melanoma recurrence or death. But markets do not evaluate clinical results in isolation. They compare them with prior evidence, and the earlier Phase 2b study showed a 49% reduction.

The seven-percentage-point difference is central to the reaction. It does not erase the Phase 3 result, but it does show why the market responded negatively despite a positive reduction in risk. For a stock that had climbed more than 500% before the data release, expectations were likely an important part of the trading equation described in the report. The issue is less whether the result was positive in absolute terms and more whether it met the standard implied by the earlier study and the stock’s advance.

The TradingKey report on Moderna’s melanoma vaccine data and technical setup identifies $181.36 as the reported support level traders are watching after the selloff.

$181.36 becomes the trading focal point

Support matters here because it gives the market a specific level for measuring the stock’s response to the clinical-data disappointment. Moderna was reported to be holding $181.36, making that price the immediate reference point rather than a forecast or a new target.

• Above the level: Holding $181.36 could suggest that traders are absorbing the weaker-than-expected comparison without fully abandoning the prior advance.
• At the level: Continued trading around $181.36 would keep the stock’s technical setup tied closely to the market’s interpretation of the Phase 3 result.
• Below the level: A failure to hold could indicate that the selloff is exerting greater pressure, although the supplied report does not provide a further price target or downside projection.

This is why the setup is more nuanced than a simple positive-versus-negative clinical headline. The Phase 3 result delivered a 42% reduction in risk, yet the comparison with the 49% Phase 2b result created a credibility and expectations issue. The prior gain of more than 500% amplified that sensitivity.

What traders are measuring now

For $MRNA, the immediate question is whether the reported $181.36 support level can continue to contain the market’s response. A hold may suggest that investors view the Phase 3 result as sufficiently supportive despite the decline from Phase 2b. A break could show that the difference between early- and late-stage data is carrying more weight.

The data therefore creates a two-part test: clinical interpretation and technical confirmation. Until the market moves beyond the reported support reference, $181.36 remains the cleanest gauge of whether Moderna’s prior advance can stabilize after the melanoma update.